Results 41 to 50 of about 4,412 (151)

Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study

Vaccines, 2022
Many available SARS-CoV-2 vaccines demonstrated good humoral response, but studies directly comparing their immunogenicity in the general population are lacking.
Vladimir Petrović, Vladimir Vuković, Aleksandra Patić, Miloš Marković, Mioljub Ristić   +4 more
doaj   +1 more source

Current State of Developed COVID-19 Vaccines; Light at the End of the Tunnel [PDF]

, 2021
COVID-19 pandemic has posed a dire threat to global health. Safe and effective vaccination can play an important role in preventing the transmission of the virus, SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus type 2).
Aleksandra Dimitrova, Kaveh Nasiri
core   +2 more sources

The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults

Frontiers in Microbiology, 2022
Vaccination is one of the best ways to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. Among the various SARS-CoV-2 vaccines approved for use, the BBIBP-CorV inactivated vaccine has been widely used in 93 countries.
Qinjin Wang, Jie Ning, Ying Chen, Bin Li, Liang Shi, Taojun He, Fang Zhang, Xingchi Chen, Aixia Zhai, Chao Wu   +9 more
doaj   +1 more source

Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans [PDF]

, 2021
Vaccine development has become the main tool for reducing COVID-19 cases and the severity of the disease. Comparative analyses of adaptive immunity generated by different vaccines platforms are urgently needed.
Galvan, Veronica, Quarleri, Jorge Fabian
core   +1 more source

The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates

Scientific Reports, 2022
Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE.
Nawal Al Kaabi, Abderrahim Oulhaj, Farida Ismail Al Hosani, Shamma Al Mazrouei, Omer Najim, Salah Eldin Hussein, Jehad Saleh Abdalla, Mohammed Saifuddin Fasihuddin, Afnan Abdellatif Hassan, Gehad Elghazali, Ahmed Al Rumaithi, Jumana Al Azazi, Stefan Weber, Rami Beiram, Khatija A. Parekh, Mohamud Sheek-Hussein, Yunkai Yang, Yang Xiaoming, Jenny Quliang, Islam Eltantawy, Sally Mahmoud, Ashish Koshy, Peng Xiao, Subhashini Ganesan, Wael Elamin, Walid Zaher   +25 more
doaj   +1 more source

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trialResearch in context

EClinicalMedicine, 2023
Summary: Background: COVID-19 vaccines that offer broad-spectrum protection are needed. We aimed to evaluate the safety and immunogenicity of multivalent vaccines, SCTV01E and SCTV01C, and compare them with an inactivated vaccine.
Suad Hannawi, Lixin Yan, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Miaomiao Zhang, Cuige Gao, Yuanxin Chen, Wenlin Gai, Liangzhi Xie   +11 more
doaj   +1 more source

SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated naïve and convalescent lactating participants [PDF]

, 2022
Background: Recent studies have shown the presence of SARS-CoV-2-specific antibodies in the milk of breastfeeding mothers vaccinated with mRNA and convalescent.
Albano, Daniel Rodolfo, Antivero Battistelli, Rocío B., Gamarnik, Andrea Vanesa, Guevara, Eleonora, Longueira, Yesica Soledad, Ojeda, Diego Sebastian, Oviedo Rouco, Santiago, Pando, María de los Ángeles, Sanchez, Lautaro, Valls, Vanesa   +9 more
core   +1 more source

Heterologous adenovirus-vector/messenger RNA regimen is associated with improved severe acute respiratory syndrome coronavirus 2 humoral response in liver transplant recipients [PDF]

, 2022
Knowledge of the immunogenicity of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in liver transplant recipients (LTRs) is mainly limited to messenger RNA (mRNA)-based types.
Abraldes, Juan G., Alter, Adriana, Anders, Margarita, Barbero, Manuel, Benencio, Paula, Biglione, Mirna Marcela, Cairo, Fernando, Ducasa, Nicolás, Etcheves, Patricia, Mauro, Ezequiel, Mendizabal, Manuel, Scarton, Giampaolo   +11 more
core   +1 more source

Systematic review of the oral manifestations produced by the SARS-CoV-2 vaccine [PDF]

, 2023
To combat the coronavirus pandemic different vaccines have been developed. However, diverse adverse effects have been reported due to their use, including oral manifestations.
Leco Berrocal, María Isabel, López Carriches, Carmen, Santana-Torres, Tomás, Taheri, Ricardo Bahram   +3 more
core   +1 more source

Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia

Vaccines, 2022
Real-world evidence of the vaccine effectiveness (VE) of different COVID-19 vaccines is needed in order to better shape vaccine recommendations and policies and increase vaccine acceptance, especially among vulnerable populations such as the elderly.
Vladimir Petrović, Vladimir Vuković, Miloš Marković, Mioljub Ristić   +3 more
doaj   +1 more source